Materiales avanzados: ¿Biomateriales seguros o dispositivos médicos certificados

To talk about biomaterials and their development, we would have to remember the history that humanity has traversed to reach the era of advanced materials. We are a post-pandemic civilization that carries the experience of an industrial revolution, two world wars, two atomic bombs, an aerospace race, and at least 150 years of documented scientific history. Each of these events has driven the generation of better and more tools, so it is not surprising that life expectancy has progressively increased, from 34 years in 1913 to 75 years in 2022 [1]. However, evaluating the biological response of a material over time and circumstances has been and continues to be a challenge for the scientific community. Let\u27s not go far; we are still observing and awaiting the effects of vaccines that were administered to a large portion of the world\u27s population against SARS-CoV-2. We are sitting, watching from the sidelines, hoping that serious side effects or new health alerts do not arise.Para hablar de biomateriales y su desarrollo, tendríamos que recordar la historia que como humanidad hemos transitado para llegar a la era de los materiales avanzados. Somos una civilización postpandemia, que carga a cuestas la experiencia de una revolución industrial, dos guerras mundiales, dos bombas atómicas, una carrera aeroespacial y al menos 150 años de historia científica documentada. Cada uno de estos eventos ha impulsado la generación de mejores y más herramientas, por lo que no es una sorpresa que la esperanza de vida haya incrementado progresivamente, desde los 34 años en 1913 hasta los 75 años en 2022 [1]. Sin embargo, evaluar la respuesta biológica de un material a lo largo del tiempo y las circunstancias ha sido y continúa siendo un reto para la comunidad científica. No vayamos lejos, aún seguimos observando y esperando los efectos de las vacunas que fueron administradas a una gran cantidad de la población mundial contra el SARS-CoV-2, esperamos sentados desde la tribuna, rogando para que no se presenten efectos secundarios graves o nuevas alertas sanitarias

Chitosan gold nanoparticles induce cell death in HeLa and MCF-7 cells through reactive oxygen species production

Background: Nanotechnology has gained important interest, especially in the development of new therapies; the application of gold nanoparticles (AuNPs) in the treatment and detection of diseases is a growing trend in this field. As cancer represents a serious health problem around the world, AuNPs are studied as potential drugs or drug carriers for anticancer agents. Recent studies show that AuNPs stabilized with chitosan (CH) possess interesting biological activities, including potential antitumor effects that could be selective to cancer cells. Materials and methods: In this study, we synthesized sodium citrate-AuNPs and CHcapped AuNPs of 3–10 nm, and analyzed their cytotoxicity in cervical (HeLa) and breast (MCF-7) cancer cells, and in peripheral blood mononuclear cells (PBMCs). Then, we evaluated the clonogenic potential, cell cycle, nuclear alterations, caspase dependence, and reactive oxygen species (ROS) production in HeLa and MCF-7 cells after chitosan gold nanoparticles (CH-AuNPs) exposure. Results: Our data showed that CH-AuNPs are cytotoxic in a dose-dependent manner in the cancer cell lines tested, while they induce low cytotoxicity in PBMCs. Sodium citrate gold nanoparticles did not show cytotoxic effects. In both HeLa and MCF-7 cell lines, CH-AuNPs inhibit clonogenic potential without inducing cell cycle arrest or nuclear alterations. The cell death mechanism is specific for the type of cancer cell line tested, as it depends on caspase activation in HeLa cells, whereas it is caspase independent in MCF-7 cells. In all cases, ROS production is mandatory for cell death induction by CH-AuNPs, as ROS inhibition with N-acetyl cysteine inhibits cell death. Conclusion: Our results show that CH-AuNPs are selective for HeLa and MCF-7 cancer cells, rather than normal PBMCs, and that ROS production seems to be a conserved feature of the cell death mechanism induced by CH-AuNPs. These results improve the knowledge of CH-AuNPs and open the way to the design of new pharmacological strategies using these agents against cancer. Keywords: AuNPs, cancer, PBMC, nuclear alterations, cell cycle, RO

Clinical trial evaluating the effectiveness of biocompound IMMUNEPOTENT CRP in the third-molar extraction

ABSTRACT A controlled, parallel, randomized and comparative trial was carried out to evaluate the antiinflammatory efficacy of IMMUNEPOTENT CRP versus ibuprofen in patients after third-molar surgery over seven days. The anti-inflammatory efficacy of IMMUNEPOTENT CRP was evaluated using the method of Amin and Laskin, and the analysis of cytokine production (IL-2, IL-4, IL-6, IL-10, TNF-a, INF-g) in saliva was done by flow cytometry. The swelling process after surgery was significant (p < 0.05) and the treatments with IMMUNEPOTENT CRP or ibuprofen controlled this process properly; no difference between the groups was found (p < 0.05). Both treatments were shown to modulate the cytokine production. These results demonstrate the anti-inflammatory activity of the natural compound IMMUNEPOTENT CRP and suggest it could be used in clinical dental practice